Pre-made Valanafusp benchmark antibody ( Whole mAb Fusion, anti-INSR therapeutic antibody, Anti-CD220/HHF5 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-608
Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Valanafusp alpha is a BBB-penetrating form of IDUA, and is designed to deliver the IDUA enzyme to brain cells to reverse the accumulation of heparan sulfate (HS) GAGs and lysosomal inclusions. The primary therapeutic goal of valanafusp alpha therapy is stabilization of cognitive decline in severe MPSI.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody|
|Format||Whole mAb Fusion|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||5kqv:PQ:CD/4zxb:CD|
|95-98% SI Structure||3loh:CD/2dtg:CD/3w14:CD:PQ|
|Conditions Active||Mucopolysaccharidosis I|